Therapeutic Goods Administration

The Therapeutic Goods Administration (TGA) is the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia.[1] It is a Division of the Australian Department of Health established under the Therapeutic Goods Act 1989 (Cth).[2][3] The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.

Therapeutic Goods Administration
Agency overview
Formed1989
JurisdictionCommonwealth of Australia
Annual budgetA$139 million (2015)
Parent departmentDepartment of Health
Websitewww.tga.gov.au

TGA Expert Advisory Committees

The TGA has nine different statutory expert committees it may call upon to obtain independent advice on scientific and technical matters, including:

  • Advisory Committee on Biologicals (ACB)
  • Advisory Committee on Complementary Medicines (ACCM)
  • Advisory Committee on Medical Devices (ACMD)
  • Advisory Committee on Non-prescription Medicines (ACNM)
  • Advisory Committee on Prescription Medicines (ACPM)
  • Advisory Committee on the Safety of Medical Devices (ACSMD)
  • Advisory Committee on the Safety of Medicines (ACSOM)
  • Advisory Committee on the Safety of Vaccines (ACSOV)
  • Therapeutic Goods Committee (TGC) – advises the Minister on standards for therapeutic goods, including labelling and packaging, and on principles to be observed in the manufacture of therapeutic goods for use in humans.

Trans-Tasman harmonisation

The governments of Australia and New Zealand were working towards establishing a Trans-Tasman joint agency for the regulation of drugs and therapeutic goods to replace the TGA and New Zealand's Medsafe. However, on 16 July 2007, the New Zealand State Services Minister Annette King announced that "The Government is not proceeding at this stage with legislation that would have enabled the establishment of a joint agency with Australia to regulate therapeutic products". She further advised that "The [New Zealand] Government does not have the numbers in Parliament to put in place a sensible, acceptable compromise that would satisfy all parties at this time. The Australian Government has been informed of the situation and agrees that suspending negotiations on the joint authority is a sensible course of action". Further details are available at the Australia New Zealand Therapeutic Products Authority (ANZTPA) website.

gollark: Also because any big change would probably ruin *something*.
gollark: I imagine it might be that because:old and TJ09 probably never stopped to refactorit's a complex game with interdependency everywherePHPhe said so in that
gollark: Yep!
gollark: Basically, where everything depends on other stuff in crazy ways and new features are bolted on without stopping to rethink stuff.
gollark: X depends on Y depends on Z depends on W depends on Y depends on X depends on Z etc.

See also

References
  1. "About the TGA". Department of Health Therapeutic Goods Administration.
  2. "About the Australian therapeutic goods legislation". Department of Health Therapeutic Goods Administration.
  3. Therapeutic Goods Act 1999 (Cth)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.